Published in final edited form as:

Tissue Eng. 2003 August ; 9(4): 745–756. doi:10.1089/107632703768247421.

Platelet-Derived Growth Factor Gene Delivery Stimulates *ex Vivo* Gingival Repair

ORASA ANUSAKSATHIEN, D.D.S., D.Med.Sc., SARAH A. WEBB, B.A., QI-MING JIN, D.D.S., Ph.D., and WILLIAM V. GIANNOBILE, D.D.S., D.Med.Sc.

Center for Craniofacial Regeneration and Department of Periodontics, Prevention, and Geriatrics, School of Dentistry, University of Michigan, Ann Arbor, Michigan.

Abstract

Destruction of tooth support due to the chronic inflammatory disease periodontitis is a major cause of tooth loss. There are limitations with available treatment options to tissue engineer soft tissue periodontal defects. The exogenous application of growth factors (GFs) such as platelet-derived growth factor (PDGF) has shown promise to enhance oral and periodontal tissue regeneration. However, the topical administration of GFs has not led to clinically significant improvements in tissue regeneration because of problems in maintaining therapeutic protein levels at the defect site. The utilization of PDGF gene transfer may circumvent many of the limitations with protein delivery to soft tissue wounds. The objective of this study was to test the effect of PDGF-A and PDGF-B gene transfer to human gingival fibroblasts (HGFs) on *ex vivo* repair in three-dimensional collagen lattices. HGFs were transduced with adenovirus encoding PDGF-A and PDGF-B genes. Defect fill of bilayer collagen gels was measured by image analysis of cell repopulation into the gingival defects. The modulation of gene expression at the defect site and periphery was measured by RT-PCR during a 10-day time course after gene delivery. The results demonstrated that PDGF-B gene transfer stimulated potent (>4-fold) increases in cell repopulation and defect fill above that of PDGF-A and corresponding controls. PDGF-A and PDGF-B gene expression was maintained for at least 10 days. PDGF gene transfer upregulated the expression of phosphatidylinositol 3-kinase and integrin α_5 subunit at 5 days after adenovirus transduction. These results suggest that PDGF gene transfer has potential for periodontal soft tissue-engineering applications.

INTRODUCTION

Periodontitis, a major cause of tooth loss, is a chronic inflammatory disease leading to destruction of tooth-supporting structures. Current modes of treatment essentially halt the disease progression with limited success in regeneration of the lost tissue. The use of growth factors (GFs) to reengineer periodontal tissue has been reviewed.¹ Application of platelet-derived growth factor BB (PDGF-BB) alone or in combination with insulin-like growth factor I (IGF-I) to treat periodontal defects resulted in partial regeneration of periodontal tissues including periodontal ligament (PDL), cementum, and bone in both animal and human studies.^{2–5} However, one problem with current growth factor delivery to periodontal wounds is the short half-life of the factors. Topical delivery of GFs remains in periodontal defects for a limited duration, possibly because of proteolytic cleavage, and the solubility of the carrier.⁶ It has been shown that long-term delivery of GFs by gene transfer provides a more sustained delivery above that of GF protein application.^{7–9} Thus, gene therapy may achieve greater bioavailability of GFs within periodontal wounds with resultant improvements in periodontal regeneration.

PDGF has been studied for gene delivery to successfully promote soft tissue repair.^{7,9,10} PDGF is a potent stimulator of fibroblast cell migration, mitogenesis, proliferation, and matrix synthesis important in wound healing.¹¹⁻¹³ The biological activities of PDGF are mediated through two intrinsic tyrosine kinase receptors (PDGF α R and PDGF β R) that induce several sets of signaling molecules, such as phosphatidylinositol-3-kinase (PI3 kinase).^{14,15} Adenovirus encoding GFs is being considered for wound repair in order to achieve high but transient transgene expression. *In vitro* studies performed by our group have shown that adenovirus encoding PDGF delivered to cells derived from periodontal tissues (gingival and PDL fibroblasts, cementoblasts, and osteoblasts) elicits elevated and prolonged PDGF gene expression for at least 1 week.^{16,17} Ad/PDGF enhanced in all cell types mitogenic and proliferative activities that were sustained above that of PDGF protein. Furthermore, Ad/PDGF gene transfer resulted in sustained tyrosine kinase phosphorylation and downregulation of the growth arrest-specific (*gas*) gene product PDGF α R for at least 96 h.¹⁸

This study sought to test the effect of gene transfer by adenovirus encoding PDGF-A and PDGF-B on human gingival fibroblast (HGF) repopulation and resultant wound fill in a three-dimensional *ex vivo* wound-healing model. Furthermore, we evaluated the effect of PDGF gene transfer on the regulation of genes associated with tissue repair such as collagen type I, PI3 kinase, and integrin α_5 subunit. This new system may provide a methodology to better determine the role of PDGF transgenes in oral and periodontal repair.

MATERIALS AND METHODS

Cell culture and recombinant adenovirus encoding PDGF constructs

The primary human gingival fibroblasts (HGFs) used in this study were a kind gift from M. Somerman (University of Washington, Seattle, WA). HGFs were derived from healthy gingivae of a human gingival tissue biopsy, and used from passages 4–6. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM; GIBCO-BRL Life Technologies, Grand Island, NY) supplemented with 10% fetal calf serum (FCS; Gemini Bio-Products, Woodland, CA), L-glutamine (2 mM), and antibiotics (penicillin [100 units/mL] and streptomycin [100 μ g/mL]; GIBCO-BRL) in a humidified atmosphere of 5% CO₂ in air at 37°C. Ad/GFP and Ad/PDGF-A viruses were constructed as previously described¹⁶ and Ad/PDGF-B was kindly donated by Selective Genetics (San Diego, CA).

Fabrication of fibroblast-populated collagen lattices

Three-dimensional fibroblast-populated collagen lattices (FPCLs) were fabricated according to a method adapted from Al-Khateeb *et al.*¹⁹ The FPC gel was mixed on ice containing rat tail tendon collagen type I (1.5 mg/mL; BD Biosciences, Bedford, MA), 1% 1 M NaOH, 2 $\times$ DMEM diluted to 1 $\times$, antibiotics (penicillin [100 units/mL] and streptomycin [100 μ g/mL]), and 3.5×10^4 HGFs/mL. Three-dimensional FPCLs were fabricated by plating 0.5 mL of FPC gel into individual 22-mm-diameter cell culture plates followed by polymerization at 37°C for 1–2 h. DMEM supplemented with 1% platelet-poor plasma (PPP), L-glutamine (2 mM), and antibiotics (penicillin [100 units/mL] and streptomycin [100 μ g/mL]) was added and the lattices were incubated overnight.

Fabrication of wounded bilayered model and HGF gene transfer

The acellular collagen lattices were fabricated in 12-well tissue culture plates according to the above-described protocol 1–2 h before preparing the wounded bilayered model. Each FPCL was “wounded,” using a 6-mm biopsy punch (George Tiemann, Hauppauge, NY), and carefully overlaid onto the acellular collagen lattice, using 80 μ L of freshly prepared collagen gel solution as an interposing adhering medium (Fig. 1A). All excess collagen gel in the wound area was removed. Forty microliters of collagen gel alone (NT), or collagen gel containing 3.5×10^6

plaque-forming units (PFU) of Ad/GFP, Ad/PDGF-A, or Ad/PDGF-B per milliliter was applied to each of the tissue defects (20 multiplicities of infection [MOI]/wound; Fig. 1A). The wounded bilayered lattice (WBLL) was incubated for an additional ~2 h to allow for complete polymerization followed by addition of 1.5 mL of DMEM containing 1% PPP. The medium was changed on days 3, 5, 7, and 10 after wounding. A total of 12 WBLLs were fabricated for each treatment group to allow for multiple analyses including cell counting, image analysis, and RNA harvest for gene expression analysis.

Cell quantification of HGFS in ex vivo gingival defects after PDGF gene delivery

Ten days after gene transfer, each FPCL in the defect area was separated and dissected from the defect periphery, using a 6-mm biopsy punch placed over the original defect (i.e., defect area); cells outside this zone were termed the “defect periphery” (Fig. 1A). HGFs were recovered from the FPCLs via collagenase digestion as previously described.¹⁹ Briefly, the FPCLs were digested with collagenase type XI (2 mg/mL; Sigma, St. Louis, MO) at 37°C for 1 h, followed by incubation for 20 min with 0.2% (w/v) trypsin and 5 mM ethylenediaminetetraacetic acid. The cells were then pelleted and resuspended in phosphate-buffered saline (pH 7.4). HGF cell numbers yielded from the wound defect and wound periphery areas were measured separately with a Neubauer hemocytometer; $n = 4$ samples of each treatment group were measured.

HGF cell repopulation into gingival defects after PDGF gene delivery as measured by computer-assisted image analysis

Standardized 20× images of HGFs that repopulated the defect area were captured on days 3, 5, 7, and 10, using a digital camera (Nikon E990; Nikon, Melville, NY) fitted to an inverted microscope (Nikon TMS) with a fixed aperture. The images were coded for masked computer-assisted image analysis, using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD), to determine HGF wound fill and cell density in the wound area at each time point. A single, calibrated examiner evaluated all the images and demonstrated a pre- and poststudy calibration intraexaminer error of <5%. HGF repopulation (defect fill) was determined by measuring the mean distance of cell repopulation into the wound area from the wound margin compared with the mean diameter of the defect area. Cell density in the defect area was determined by measuring five standardized areas of interest (AOI) at 1 mm² each directly across the horizontal diameter of the defect. The first two AOIs were measured at the wound margin, then another two AOIs were measured at the areas adjacent to the peripheral regions and one AOI was measured in the direct center of the wound area. The summation of cell density from each AOI was performed and the mean values were generated for each group. The images were uncoded and then analyzed using one-way analysis of variance (ANOVA) and Fisher's protected least significant difference (PLSD) to determine the differences among groups.

Effect of Ad/PDGF-A and -B gene transfer on HGF gene expression

To examine the transgene transduction efficiency and the modulation of gene expression after Ad/PDGF-A and -B delivery to HGFs, reverse transcriptase-polymerase chain reaction (RT-PCR) experiments were performed. On days 5 and 10, the wound areas of two WBLLs from each experiment were harvested with a 9-mm biopsy punch to include the wound site and 1.5-mm zone peripheral to the defect. Total RNA was extracted from HGFs, using TRIzol reagent (GIBCO-BRL). One microgram of RNA was reverse transcribed in a 20-μL RT reaction, using a Retroscript kit (Ambion, Austin, TX). RT-PCR was performed to determine the expression of the following genes: PDGF-A, PDGF-B, collagen type I α_1 chain (COL1 α_1), the α subunit of PI3 kinase (P85 α), and integrin α_5 subunit (α_5). The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to assess the relative loading of the mRNA

samples. The primer pairs for each gene and the expected PCR products are shown in Table 1. A total volume of 25 μ L of the PCR was mixed with 5 μ L of RT product, 1 $\times$ PCR buffer (10 mM Tris-HCl [pH 9.0], 50 mM KCl, and 0.1% Triton X-100), 100 μ M dNTPs, 750 μ M MgCl₂, primers (1 μ M each), and 0.5 unit of *Taq* DNA polymerase (Promega, Madison, WI), using a PerkinElmer thermocycler 9600 (PerkinElmer, Norwalk, CT). The PCR conditions for detecting expression of PDGF-B were 94°C for 2 min, 45 cycles of 94°C for 30 s, 60°C for 1 min, followed by 72°C for 10 min. The forward primer of PDGF-B was located at the 3' end of the PDGF-B gene and the reverse primer included the Ad/PDGF-B virus backbone. The PCR conditions for the other genes were 94°C for 2 min, 30 cycles of 94°C for 30 s, 57°C for 45 s, and 72°C for 45 s, followed by 72°C for 10 min. Ten microliters of PCR product was separated on 1.5% agarose gels in TBE buffer and visualized by staining with ethidium bromide. The relative ratio of gene expression was normalized with GAPDH, using the NIH Image 1.62 program.

RESULTS

In the present study, a three-dimensional collagen lattice wound-healing model was fabricated *in vitro*, using HGF cells, to examine the effect of PDGF-A and -B adenovirus gene transfer to promote *ex vivo* gingival repair. A 6-mm wound was created in three-dimensional FPCLs to determine the repopulation of HGFs into the defects for up to 10 days. The expression on day 7 post treatment of a reporter gene, GFP, transduced by Ad/GFP in HGFs is depicted in Fig. 1B and C. A phase-contrast image of the defect margin where HGFs repopulated into the defect area is shown in Fig. 1B. There are a number of HGF cells transduced with Ad/GFP in the defect area and at the wound edge that correspond to the fluorescence image in Fig. 1C.

Representative images of HGFs that repopulated the wound area on day 10 from each treatment are depicted in Fig. 2. The images show the greatest density of HGF cells occupying the wound area in the Ad/PDGF-B group as compared with the other treatments. The Ad/PDGF-A treatment did not significantly enhance cell repopulation in the wound area compared with the NT or Ad/GFP-treated defects. Several parameters were determined by image analysis. The rate of defect fill was measured to determine the HGF cell migratory rate over 10 days (Fig. 3). Defect fill progressively increased up to 72% in the Ad/PDGF-B treated wounds over 10 days. The result showed a significantly more rapid defect fill in the Ad/PDGF-B-treated wounds as compared with the other treatments at all time points ($p < 0.001$). Beyond day 10, many of the lattices began to experience contracture at the peripheral regions, preventing longer term assessment. No significant differences were noted in contracture of the internal wound areas at all time points ($p > 0.05$).

The effect of Ad/PDGF-A and -B gene transfer on cellular migration and proliferation was determined by measuring total cell density of HGFs that repopulated the defect area, using image analysis (Fig. 4). Significantly greater cell density was detected in the Ad/PDGF-B-treated defects compared with the other treatments at all time points ($p < 0.001$). In addition, cell counting on day 10 was determined in two separate areas including the defect area, and the defect periphery (Table 2). Compared with all treatment groups, Ad/PDGF-B stimulated the greatest increases in cell repopulation in the defect area and defect periphery ($p < 0.001$).

The prolonged transduction of PDGF genes by Ad/PDGF-A and -B gene transfer in HGFs was examined by RT-PCR (Fig. 5). HGF gene expression of both PDGF-A and PDGF-B genes was induced over a period of 10 days in Ad/PDGF-A- and Ad/PDGF-B-treated defects, respectively. No significant change in expression of COL1 α 1 was observed in both the Ad/PDGF-A- and Ad/PDGF-B-treated defects during the experimental period (Fig. 6A). Upregulation of the PI3 kinase P85 α subunit and integrin α ₅ genes was observed in the Ad/PDGF-B-treated defects on day 5. No changes were observed in the level of expression for

these two genes by day 10 in the Ad/PDGF-B-treated wounds (Fig. 6B). No significant changes in PI3 kinase P85 α subunit and integrin α_5 expression were noted after PDGF-A gene transfer. The results showed that upregulation of PI3 kinase and integrin α_5 subunit in response to PDGF-B gene transfer may be involved in the promotion of the early wound-healing process. However, the direct effects of PDGF-B gene transfer on these signaling pathways were not specifically measured.

DISCUSSION

We have established an artificial three-dimensional wound model to test the effects of Ad/PDGF-A and -B gene transfer to gingival cells derived from healthy periodontal tissue. This model was developed to directly apply growth factor vector immobilized in a soluble matrix to a wound site to serve as a scaffold for invading cells. Subsequent transduction of these cells would then allow for transgene expression and formation of new tissue within the matrix scaffold. This mimicks the *in vivo* situation in which PDGF is released or incorporated in the wound site and elicits activities toward the surrounding target cell types. The results show the effective prolonged expression of PDGF-A, PDGF-B, and green fluorescent protein genes delivered by adenovirus over a period of 7–10 days in the wound sites (Figs. 1C and 5). It is consistent with our previous work and others showing the sustained production of PDGFs delivered by adenovirus.^{9,16,17} The GF produced in this wound model is presumably locally produced within the wound and released into the culture medium, affecting neighboring cells in an autocrine, paracrine, and delayed paracrine manner. We have previously shown that PDGF protein production is approximately 200 ng/10⁶ fibroblasts per day.¹⁸ Further studies will be necessary to determine differences in expression of PDGF receptors in diseased and regenerating tissues known to be modulated in these situations.^{20,21}

The Ad/PDGF-B-treated wounds exhibited the greatest degree of wound fill by increasing HGF repopulation into the wound defect area. There was a 2-fold increased rate of defect fill in the Ad/PDGF-B group compared with all other groups, including Ad/PDGF-A. Our data are consistent with many *in vitro* and *in vivo* studies relating to PDGF and soft tissue repair. PDGF-AB has been shown to be a strong chemotactic factor for gingival fibroblasts in the *in vitro* Boyden chamber system.²² In addition, it has been demonstrated that PDGF-BB elicited a dramatic increase in wound closure in several animal models.^{7,9,10} For example, application of PDGF-B encoded by plasmid or adenovirus DNA vector impregnated in collagen matrix induced ~2.5 times greater wound closure in the 6- or 8-mm ischemic skin wounds in rabbits as compared with the negative control.^{9,10} Our results using the *in vitro* model are consistent with the degree of wound closure induced by PDGF-B gene transfer in extraoral soft tissue wounds.

Image analysis showed approximately 4-fold greater cell densities of HGFs that repopulated the defect area in the Ad/PDGF-B-treated sites as compared with the other groups. In addition, Ad/PDGF-B significantly enhanced cellular density in the defect area on day 10 as determined by cell measurement. Mumford and co-workers created a 3-mm defect on tissue culture plastic and showed significantly greater percentages of cell density of HGFs in response to a variety of PDGF-BB concentrations compared with controls over a period of 9 days when PDGF-BB was continuously added to the medium.²³ However, they reported that PDGF-BB did not induce higher cellular proliferation of HGFs as compared with control. Thus, the rapid wound fill in their *in vitro* wound model might occur by activation of cellular migration in response to PDGF-BB rather than cellular proliferation. In addition, it has been shown that HGFs grown in collagen gels exhibit no significant increase cellular proliferation in response to PDGF-BB compared with negative controls on day 14.²⁴ Although we did not directly measure cell migration and proliferation separately, we found that HGF cells transduced with Ad/PDGF-B repopulated the defects more rapidly than the corresponding controls, including Ad/PDGF-A.

The stimulatory effects of PDGF on cell migration and proliferation are mediated through two receptors designated as α and β receptors. PDGF-A binds only to PDGF- α R, and PDGF-B binds to both α and β receptors.¹⁵ PDGF-A and -B have been shown to be expressed in gingival wounds for up to 3 days postwounding. PDGF- α R was minimally detectable, whereas PDGF- β R was upregulated and became maximal after 7 days.²⁰ Furthermore, PDGF- α R was not measurable in cultured gingival and periodontal ligament fibroblasts, but PDGF- β R appeared to be highly expressed in the 6-week human regenerated periodontal tissues compared with gingival and periodontal ligament tissues.²¹ This likely explains the limited response of HGFs to Ad/PDGF-A gene transfer in this model.

It has been shown that stimulation of granulation tissue formation by PDGF-A plasmid DNA was comparable to that found with PDGF-B.¹⁰ Our *in vitro* results showed significantly less defect fill induced by Ad/PDGF-A. Possible explanations are as follows: (1) In general, PDGF-BB possesses a more potent stimulatory effect on cellular migration, and induces proliferation greater than PDGF-AA or PDGF-AB;²⁵⁻²⁷ (2) induction of cell growth by PDGF-AA or Ad/PDGF-A requires additional growth factors present in serum; our system was devoid of progression factors such as IGF-I^{18,28,29}; and (3) PDGF-AA binds selectively to PDGF- α receptors; it has been shown that homodimers of PDGF- α receptor does not mediate chemotaxis in many cell types.^{30,31} It is possible that PDGF-AA does not induce migration of HGF, especially in this three-dimensional wound model. Although expression of PDGF- α R and - β R was not determined in the present study, these results suggest that PDGF-BB or -AB that bind to PDGF- β R may play a greater role in periodontal wound healing.

One of the important steps in the wound repair process is synthesis of extracellular matrix proteins, such as collagen type I, by connective tissue cells.^{32,33} Our results revealed that the level of COL1 α 1 gene expression in HGFs did not significantly change over a period of 10 days in any treatment. Several *in vitro* studies have shown that PDGFs do not directly regulate collagen type I gene expression by fibroblasts.^{34,35} Our result was consistent with that reported by Irwin and coworkers, who found no difference in collagen production between the negative control (2.5% FCS) and PDGF-BB treatment when HGFs were incorporated in the collagen lattice.²⁴ Also, PDGF-BB did not induce COL1 α 1 mRNA expression in dermal fibroblasts incorporated in collagen gels while increasing collagen type I protein synthesis.³⁶ Although elevated production of collagen has been shown *in vivo* in response to PDGF treatment,³⁷ this result may be related to the increased number of fibroblasts in the wounds, not the cellular activity per se.^{34,38}

Phosphatidylinositol-3-kinase is an important secondary messenger that regulates cellular migration and proliferation in response to PDGF in many cell types.³⁹⁻⁴¹ The regulatory P85 α subunit of PI3 kinase has been shown to directly interact with activated PDGF α R and PDGF β R.^{42,43} Also, increased levels of phosphorylated P85 α subunit of PI3 kinase protein activated by PDGF receptor have been detected.^{43,44} It has been shown that PDGF-BB induces NIH 3T3 fibroblast cell migration on collagen gels mediated by the P85 α subunit of PI3 kinase.⁴⁵ Our study revealed that PI3 kinase was upregulated on day 5 and remained relatively unchanged after PDGF-B gene transfer as compared with the other groups (Fig. 6). Although the activation state of PI3 kinase P85 α subunit was not determined, it is consistent with rapid rates of HGF repopulation in the Ad/PDGF-B-treated defects from days 3–5 with minimal subsequent changes in defect fill rate from days 5 to 10. A serine-threonine protein kinase (Akt) is an important PI3 kinase dependent on downstream signaling molecule for PDGF.¹⁵ Our group has shown that Ad/PDGF induces sustained phosphorylation of Akt for up to 96 h in fibroblasts.¹⁸ Thus, our data suggest that PI3 kinase is involved in response to exposure of Ad/PDGF-B to HGF migration and proliferation in this three-dimensional artificial wound model at early time points.

It has been reported that expression of integrin α_5 was enhanced on fibroblasts adjacent to the wound and in the granulation tissue in a cutaneous wound model.⁴⁶ In our experimental gingival defect model, HGFs surrounding the defects incorporated with Ad/PDGF-A and -B presumably activated cell surface receptors of the integrin family during migration into the wound and for subsequent matrix biosynthesis. Our study shows that Ad/PDGF-B upregulates integrin α_5 subunit gene expression in HGFs on day 5 and that the level of expression was relatively similar to that of other groups at later time points (Fig. 6). Our result is consistent with other studies showing that PDGF-BB enhances the production of integrin α_5 at both the mRNA and protein level.⁴⁶⁻⁴⁸ PDGF selectively stimulates fibronectin production in fibroblast cell lines.^{49,50} Integrin $\alpha_5\beta_1$ binds to fibronectin, which is accumulated in the early phases of wound healing, and plays an important role in modulating fibroblast migration into the wound.^{51,52} It has been shown *in vitro* that fibronectin present in the collagen gel and fibrin gel is required for dermal fibroblast cells to transmigrate from the collagen gel into the surrounding fibrin gel.⁵³ Therefore, upregulation of integrin α_5 subunit by HGFs in Ad/PDGF-B-treated wounds at early time points correlates with a rapid increase in HGF repopulation into the defect area, especially from days 3 to 5 (Fig. 6).

We noted that Ad/PDGF-B-treated defects did not exhibit wound contraction, suggesting that Ad/PDGF-B incorporated in the collagen scaffold may promote wound healing with minimal scar formation. This is supported by the observation that collagen-formulated Ad/PDGF-B induced complete repair of excisional skin defects, without the development of hypertrophic scar formation.⁹ Several growth factors work in concert for optimal wound repair and lead to scar formation in most *in vivo* systems. Application of collagen-formulated Ad/PDGF-B for periodontal wound repair and regeneration awaits further study. A major consideration in using adenovirus for gene transfer is the significant cytotoxic T cell-mediated immune response that occurs when delivered *in vivo*.⁵⁴ Despite the inflammatory cell infiltrate that is notable during the early phases of wound repair, delivery of GF genes to periodontal wounds can still result in bone and ligament formation.⁵⁵ The use of second and third vector systems should aid in decreasing the influence of inflammation when adenovirus is delivered *in vivo*.

Taken together, we have established a three-dimensional wound model to locally deliver Ad/PDGF-A and Ad/PDGF-B genes to cells derived from periodontal tissue for the promotion of wound healing. The expression of PDGF genes was prolonged for up to 10 days. Ad/PDGF-B enhanced defect fill by induction of HGF migration and proliferation. The upregulation of genes associated with PDGF signaling (PI3 kinase) and fibroblast migration (integrin α_5) suggests that several cellular and molecular events are modulated in response to long-term PDGF gene delivery. *In vivo* delivery of Ad/PDGF-B incorporated in collagen scaffolds as a biomimetic device offers potential for the promotion of periodontal and oral tissue wound repair and regeneration.

ACKNOWLEDGMENTS

We thank Marie Printz from Selective Genetics (San Diego, CA) for assistance with this project. We also thank Chris Jung for preparation of the figures. This study was funded by NIH/NIDCR grants DE 11960 and 13397 and by a University of Michigan Rackham Faculty Award to W.V.G.

REFERENCES

1. Anusaksathien O, Giannobile WV. Growth factor delivery to re-engineer periodontal tissues. *Curr. Pharm. Biotechnol* 2002;3:129. [PubMed: 12022256]
2. Rutherford RB, Niekrash CE, Kennedy JE, Charette MF. Platelet-derived and insulin-like growth factors stimulate regeneration of periodontal attachment in monkeys. *J. Periodont Res* 1992;27:285. [PubMed: 1640350]

3. Giannobile WV, Finkelman RD, Lynch SE. Comparison of canine and nonhuman primate animal models for periodontal regenerative therapy: Results following a single administration of PDGF/IGF-I. *J. Periodontol* 1994;65:1158. [PubMed: 7877089]
4. Giannobile WV, Hernandez RA, Finkelman RD, Ryan S, Kiritsy CP, D'Andrea M, Lynch SE. Comparative effects of platelet-derived growth factor-BB and insulin-like growth factor-I, individually and in combination, on periodontal regeneration in *Macaca fascicularis*. *J. Periodontal Res* 1996;31:301. [PubMed: 8858534]
5. Howell TH, Fiorellini JP, Paquette DW, Offenbacher S, Giannobile WV, Lynch SE. A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. *J. Periodontol* 1997;68:1186. [PubMed: 9444594]
6. Giannobile WV. Periodontal tissue engineering by growth factors. *Bone* 1996;19:23S. [PubMed: 8830996]
7. Liechty KW, Nesbit M, Herlyn M, Radu A, Adzick NS, Crombleholme TM. Adenoviral-mediated over-expression of platelet-derived growth factor-B corrects ischemic impaired wound healing. *J. Invest. Dermatol* 1999;113:375. [PubMed: 10469337]
8. Eming SA, Whitsitt JS, He L, Krieg T, Morgan JR, Davidson JM. Particle-mediated gene transfer of PDGF isoforms promotes wound repair. *J. Invest. Dermatol* 1999;112:297. [PubMed: 10084305]
9. Doukas J, Chandler LA, Gonzalez AM, Gu D, Hoganson DK, Ma C, Nguyen T, Printz MA, Nesbit M, Herlyn M, Crombleholme TM, Aukerman SL, Sosnowski BA, Pierce GF. Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors. *Hum. Gene Ther* 2001;12:783. [PubMed: 11339895]
10. Tyrone JW, Mogford JE, Chandler LA, Ma C, Xia Y, Pierce GF, Mustoe TA. Collagen-embedded platelet-derived growth factor DNA plasmid promotes wound healing in a dermal ulcer model. *J. Surg. Res* 2000;93:230. [PubMed: 11027465]
11. Kaplan DR, Chao FC, Stiles CD, Antoniades HN, Scher CD. Platelet α granules contain a growth factor for fibroblasts. *Blood* 1979;53:1043. [PubMed: 444648]
12. Seppa H, Grotendorst G, Seppa S, Schiffmann E, Martin GR. Platelet-derived growth factor in chemotactic for fibroblasts. *J. Cell Biol* 1982;92:584. [PubMed: 7061598]
13. Heldin P, Laurent TC, Heldin CH. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. *Biochem. J* 1989;258:919. [PubMed: 2543365]
14. Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor α and β subtypes. *Growth Factors* 1999;16:201. [PubMed: 10372961]
15. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. *Biochim. Biophys. Acta* 1998;1378:F79. [PubMed: 9739761]
16. Zhu Z, Lee CS, Tejada KM, Giannobile WV. Gene transfer and expression of platelet-derived growth factors modulate periodontal cellular activity. *J. Dent. Res* 2001;80:892. [PubMed: 11379891]
17. Giannobile WV, Lee CS, Tomala MP, Tejada KM, Zhu Z. Platelet-derived growth factor (PDGF) gene delivery for application in periodontal tissue engineering. *J. Periodontol* 2001;72:815. [PubMed: 11453245]
18. Chen QP, Giannobile WV. Adenoviral gene transfer of PDGF downregulates gas gene product PDGF α R and prolongs ERK and Akt/PKB activation. *Am. J. Physiol. Cell Physiol* 2002;282:C538. [PubMed: 11832339]
19. Al-Khateeb T, Stephens P, Shepherd JP, Thomas DW. An investigation of preferential fibroblast wound repopulation using a novel in vitro wound model. *J. Periodontol* 1997;68:1063. [PubMed: 9407398]
20. Green RJ, Usui ML, Hart CE, Ammons WF, Narayanan AS. Immunolocalization of platelet-derived growth factor A and B chains and PDGF- α and β receptors in human gingival wounds. *J. Periodontal Res* 1997;32:209. [PubMed: 9089487]
21. Parkar MH, Kuru L, Giouzei M, Olsen I. Expression of growth-factor receptors in normal and regenerating human periodontal cells. *Arch. Oral Biol* 2001;46:275. [PubMed: 11165574]
22. Nishimura F, Terranova VP. Comparative study of the chemotactic responses of periodontal ligament cells and gingival fibroblasts to polypeptide growth factors. *J. Dent. Res* 1996;75:986. [PubMed: 8708140]

23. Mumford JH, Carnes DL, Cochran DL, Oates TW. The effects of platelet-derived growth factor-BB on periodontal cells in an in vitro wound model. *J. Periodontol* 2001;72:331. [PubMed: 11327060]
24. Irwin CR, Schor SL, Ferguson MW. Effects of cytokines on gingival fibroblasts in vitro are modulated by the extracellular matrix. *J. Periodontal Res* 1994;29:309. [PubMed: 7799210]
25. Matsuda N, Lin WL, Kumar NM, Cho MI, Genco RJ. Mitogenic, chemotactic, and synthetic responses of rat periodontal ligament fibroblastic cells to polypeptide growth factors in vitro. *J. Periodontol* 1992;63:515. [PubMed: 1625151]
26. Lepisto J, Laato M, Niinikoski J, Lundberg C, Gerdin B, Heldin CH. Effects of homodimeric isoforms of platelet-derived growth factor (PDGF-AA and PDGF-BB) on wound healing in rat. *J. Surg. Res* 1992;53:596. [PubMed: 1494293]
27. Lepisto J, Peltonen J, Vaha-Kreula M, Niinikoski J, Laato M. Platelet-derived growth factor isoforms PDGF-AA, -AB and -BB exert specific effects on collagen gene expression and mitotic activity of cultured human wound fibroblasts. *Biochem. Biophys. Res. Commun* 1995;209:393. [PubMed: 7733905]
28. Stiles CD, Capone GT, Scher CD, Antoniades HN, Van Wyk JJ, Pledger WJ. Dual control of cell growth by somatomedins and platelet-derived growth factor. *Proc. Natl. Acad. Sci. U.S.A* 1979;76:1279. [PubMed: 312500]
29. Karenberg TA, Fenn A, Sachinidis A, Hoppe J. The differential activation of phosphatidylinositol-3 kinase and mitogen-activated protein kinases by PDGF-AA and IGF-I might explain the synergistic effect of the two growth factors on the proliferation of AKR-2B fibroblasts. *Exp. Cell Res* 1994;213:266. [PubMed: 8020598]
30. Nister M, Hammacher A, Mellstrom K, Siegbahn A, Ronnstrand L, Westermark B, Heldin CH. A glioma-derived PDGF A chain homodimer has different functional activities from a PDGF AB heterodimer purified from human platelets. *Cell* 1988;52:791. [PubMed: 2832065]
31. Koyama N, Kinsella MG, Wight TN, Hedin U, Clowes AW. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. *Circ. Res* 1998;83:305. [PubMed: 9710123]
32. Ross R. The fibroblast and wound repair. *Biol. Rev* 1968;43:51. [PubMed: 4229841]
33. Peacock, EEJ. *Wound Repair*. W.B. Saunders; Philadelphia, PA: 1984.
34. Clark JG, Madtes DK, Raghu G. Effects of platelet-derived growth factor isoforms on human lung fibroblast proliferation and procollagen gene expression. *Exp. Lung Res* 1993;19:327. [PubMed: 8319603]
35. Tan EM, Qin H, Kennedy SH, Rouda S, Fox JWT, Moore JH Jr. Platelet-derived growth factors-AA and -BB regulate collagen and collagenase gene expression differentially in human fibroblasts. *Biochem. J* 1995;310:585. [PubMed: 7654198]
36. Ivarsson M, McWhirter A, Borg TK, Rubin K. Type I collagen synthesis in cultured human fibroblasts: Regulation by cell spreading, platelet-derived growth factor and interactions with collagen fibers. *Matrix Biol* 1998;16:409. [PubMed: 9524361]
37. Pierce GF, Tarpley JE, Yanagihara D, Mustoe TA, Fox GM, Thomason A. Platelet-derived growth factor (BB homodimer), transforming growth factor- β_1 , and basic fibroblast growth factor in dermal wound healing: Neovessel and matrix formation and cessation of repair. *Am. J. Pathol* 1992;140:1375. [PubMed: 1376557]
38. Pierce GF, Brown D, Mustoe TA. Quantitative analysis of inflammatory cell influx, procollagen type I synthesis, and collagen cross-linking in incisional wounds: Influence of PDGF-BB and TGF- β_1 therapy. *J. Lab. Clin. Med* 1991;117:373. [PubMed: 2019792]
39. Valius M, Kazlauskas A. Phospholipase C- γ_1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. *Cell* 1993;73:321. [PubMed: 7682895]
40. Choudhury GG, Karamitsos C, Hernandez J, Gentilini A, Bardgett J, Abboud HE. PI-3-kinase and MAPK regulate mesangial cell proliferation and migration in response to PDGF. *Am. J. Physiol* 1997;273:F931. [PubMed: 9435682]
41. Yamboliev IA, Chen J, Gerthoffer WT. PI 3-kinases and Src kinases regulate spreading and migration of cultured VSMCs. *Am. J. Physiol. Cell Physiol* 2001;281:C709. [PubMed: 11443070]
42. Heidaran MA, Beeler JF, Uy JC, Ishibashi T, LaRochelle WJ, Pierce JH, Aaronson SA. Differences in substrate specificities of α and β platelet-derived growth factor (PDGF) receptors: Correlation with

- their ability to mediate PDGF transforming functions. *J. Biol. Chem* 1993;268:9287. [PubMed: 8387491]
43. Marra F, Gentilini A, Pinzani M, Choudhury GG, Parola M, Herbst H, Dianzani MU, Laffi G, Abboud HE, Gentilini P. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. *Gastroenterology* 1997;112:1297. [PubMed: 9098016]
 44. Hu P, Margolis B, Skolnik EY, Lammers R, Ullrich A, Schlessinger J. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. *Mol. Cell. Biol* 1992;12:981. [PubMed: 1372091]
 45. Jimenez C, Portela RA, Mellado M, Rodriguez-Frade JM, Collard J, Serrano A, Martinez AC, Avila J, Carrera AC. Role of the PI3K regulatory subunit in the control of actin organization and cell migration. *J. Cell Biol* 2000;151:249. [PubMed: 11038173]
 46. Gailit J, Xu J, Bueller H, Clark RA. Platelet-derived growth factor and inflammatory cytokines have differential effects on the expression of integrins $\alpha_1\beta_1$ and $\alpha_5\beta_1$ by human dermal fibroblasts in vitro. *J. Cell Physiol* 1996;169:281. [PubMed: 8908195]
 47. Kirchberg K, Lange TS, Klein EC, Jungtaub H, Heinen G, Meyer-Ingold W, Scharfetter-Kochanek K. Induction of β_1 integrin synthesis by recombinant platelet-derived growth factor (PDGF-AB) correlates with an enhanced migratory response of human dermal fibroblasts to various extracellular matrix proteins. *Exp. Cell Res* 1995;220:29. [PubMed: 7545130]
 48. Harwood FL, Goomer RS, Gelberman RH, Silva MJ, Amiel D. Regulation of $\alpha_v\beta_3$ integrin receptors by basic fibroblast growth factor and platelet-derived growth factor-BB in intrasynovial flexor tendon cells. *Wound Repair Regen* 1999;7:381. [PubMed: 10564567]
 49. Blatti SP, Foster DN, Ranganathan G, Moses HL, Getz MJ. Induction of fibronectin gene transcription and mRNA is a primary response to growth-factor stimulation of AKR-2B cells. *Proc. Natl. Acad. Sci. U.S.A* 1988;85:1119. [PubMed: 3124113]
 50. Allen-Hoffmann BL, Schlosser SJ, Brondyk WH, Fahl WE. Fibronectin levels are enhanced in human fibroblasts overexpressing the c-sis protooncogene. *J. Biol. Chem* 1990;265:5219. [PubMed: 2180962]
 51. Gailit J, Pierschbacher M, Clark RA. Expression of functional $\alpha_4\beta_1$ integrin by human dermal fibroblasts. *J. Invest. Dermatol* 1993;100:323. [PubMed: 8440915]
 52. Gailit J, Clark RA. Studies in vitro on the role of α_v and β_1 integrins in the adhesion of human dermal fibroblasts to provisional matrix proteins fibronectin, vitronectin, and fibrinogen. *J. Invest. Dermatol* 1996;106:102. [PubMed: 8592057]
 53. Greiling D, Clark RA. Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix. *J. Cell Sci* 1997;110:861. [PubMed: 9133673]
 54. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. *Proc. Natl. Acad. Sci. U.S.A* 1994;91:4407. [PubMed: 8183921]
 55. Jin Q-M, Anusaksathien O, Webb SA, Rutherford RB, Giannobile WV. BMP gene therapy stimulates periodontal tissue engineering. *J. Periodontol* 2003;74:202. [PubMed: 12666709]

FIG. 1.

Fabrication of the bilayered wound defect model. **(A)** Fibroblast-populated collagen lattices (FPCLs) were fabricated and wounded with a 6-mm-diameter biopsy punch. Acellular collagen lattices were constructed and served as the inferior layer wound bed. Each FPCL was overlaid on the acellular layer followed by application of a collagen gel incorporated with 1% PPP (no treatment, NT) or 3.5×10^6 plaque-forming units (PFU)/ml (20 MOI) of adenovirus encoding either GFP, PDGF-A, or PDGF-B. Images depict HGFs migrating from the defect margin.

(B) A representative phase-contrast image depicts the wound margin of a defect treated with Ad/GFP for 7 days (original magnification, $\times 200$). Arrows indicate HGF cells transduced by Ad/GFP near the defect margin. **(C)** Fluorescence image depicts the corresponding HGF cells expressing green fluorescent protein.

FIG. 2. PDGF-B gene transfer stimulates *ex vivo* gingival defect fill. Images depict HGF repopulation into the wound defect area. Standardized digital images show HGFs filling in the wound area 10 days after no treatment (NT; **A**) or after treatment with 20 MOI of Ad/GFP (**B**), Ad/PDGF-A (**C**), or Ad/PDGF-B (**D**) per defect ($n = 4$ defects per group; original magnification, $\times 20$).

FIG. 3.

PDGF-B gene transfer stimulates *ex vivo* gingival defect fill. HGF repopulation of created defects left untreated (NT) or treated with Ad/GFP, Ad/PDGF-A, or Ad/PDGF-B was measured by computer-assisted image analysis on days 3, 5, 7, and 10 postwounding. The percentage of wound fill was measured by determining the mean distance of cell migration into the wound area compared with the mean diameter of the wound. The data represent mean and standard error of measurement at each time point. Ad/PDGF-B induced significantly higher wound fill over time ($*p < 0.001$) compared with the other groups 3, 5, 7, and 10 days after gene transfer ($n = 4$ defects per group).

FIG. 4.

Density of cell repopulation into collagen wound defects. Total cell density of HGFs that repopulated defects left untreated (NT) or treated with Ad/GFP, Ad/PDGF-A, or Ad/PDGF-B was measured by computer-assisted image analysis on days 3, 5, 7, and 10. The data represent means $\pm$ SEM. Ad/PDGF-B induced significantly higher total cell density (* p , 0.001) compared with all other groups 3, 5, 7, and 10 days after gene transfer (n = 4 defects per group).

FIG. 5. Prolonged induction of PDGF-A and PDGF-B transgenes in HGFs: day 10. RNAs extracted from HGF-populated lattices were subjected to RT-PCR. The PCR products were analyzed on ethidium bromide-stained gels and the expected PCR sizes are indicated. PDGF-A and PDGF-B genes were induced at all time points up to day 10 in the Ad/PDGF-A and Ad/PDGF-B groups, respectively.

FIG. 6.

Effect of PDGF-A and PDGF-B gene transfer on HGF gene expression by RT-PCR. RNAs extracted from HGF-populated lattices were subjected to RT-PCR with various sets of primers (Table 1) to determine the expression of ColI α 1, PI3 kinase (P85 α), and integrin α_5 subunit (α_5) compared with GAPDH (**A**) on day 5 and (**B**) on day 10. Histograms depict the relative ratio of gene expression normalized to GAPDH on day 5 (**A**, right) and day 10 (**B**, right). The PCR products were analyzed on ethidium bromide-stained gels and the expected PCR sizes are indicated. ColI α 1 expression levels were not changed appreciably in response to Ad/PDGF-A and Ad/PDGF-B during the 10-day observation period. PI3 kinase (P85 α) and integrin α_5 subunit (α_5) were upregulated in HGFs by PDGF-B induction on day 5, and remained unchanged compared with the other groups on day 10.

Table 1

Primers Used for RT-PCR Experiments

<i>Gene</i>	<i>Primer</i>	<i>PCR product (bp)</i>
PDGF-A	Forward: 5'-CCTGCCCATTTCGGAGGAAGAG-3 ' Reverse: 5'-TTGGCCACCTTGACGCTGCG-3 '	224
Ad/PDGF-B	Forward: 5'-CAAGCACACGCATGACAAGA-3 ' Reverse: 5'-TGTGAAATTTGTGATGCTATTGCTTT-3 '	131
COL1 α 1	Forward: 5'-TCCCAGAACATCACCTACCACTGC-3 ' Reverse: 5'-TGTATTCAATCACTGTCTTGCCCC-3 '	202
PI3 kinase (P85 α)	Forward: 5'-GTGGAAGATGATGAAGATTTGCCC-3 ' Reverse: 5'-AAGCCATAGCCAGTTGCTGTTTTG-3 '	215
Integrin α_5 ($\alpha 5$)	Forward: 5'-GACTACTTTGCCGTGAACCAGAGC-3 ' Reverse: 5'-GCGAGTTGTTGAGATTCTTGCTGAG-3 '	171
GAPDH	Forward: 5'-AAGTCAGAGGAGACCACCTGG-3 ' Reverse: 5'-GACAACAGCCTCAAGATCATCAGC-3 '	437

Table 2

HGF Cell Counts on Day 10 after Defect Creation

<i>Cell count (n = 4)</i>	<i>Treatment (cells × 10³ ± SEM)</i>			
	<i>NT</i>	<i>Ad/GFP</i>	<i>Ad/PDGF-A</i>	<i>Ad/PDGF-B</i>
Defect area	2.3 ± 0.4	1.3 ± 0.1	1.5 ± 0.3	4.9 ± 0.6 ^a
Defect periphery	53.1 ± 8.2	35.4 ± 5.4	49.7 ± 2.7	145.0 ± 5.0 ^b

^a $p < 0.05$; significantly different from the other treatments.

^b $p < 0.001$; significantly different from the other treatments.